Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Reply to ‘Allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome’

Bone Marrow Transplantation volume 50, pages 1483–1485 (2015)Cite this article

Subjects

With great interest we read the article of Nishihori et al.,1 in which the authors describe a patient with concurrent multiple myeloma (MM) and myelodysplastic syndrome (MDS), who achieved remission of both malignancies after allogeneic stem cell transplantation (allo-HSCT). We agree with the authors that therapeutic decision-making becomes complex when two hematological disorders are diagnosed in the same patient. This situation becomes even more complex if relapse of one or both entities occurs. To collect further experience and to help clinicians in this decision process, we here describe a patient with relapse of therapy-related MDS (tMDS) after allo-HSCT in the presence of persisting MM.

Although case reports like this or the one from Nishihori et al.1 never allow definitive conclusions, they often address important issues, which might have an impact beyond the individual case.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Nishihori T, Komrokji R, Shain K, Anasetti C . Allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome. Bone Marrow Transplant 2015; 50: 296–297.

    Article  CAS  Google Scholar 

  2. Mailankody S, Pfeiffer RM, Kristinsson SY, Korde N, Bjorkholm M, Goldin LR et al. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood 2011; 118: 4086–4092.

    Article  CAS  Google Scholar 

  3. Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol 2014; 15: 333–342.

    Article  CAS  Google Scholar 

  4. Zimmerman Z, Scott BL, Gopal AK, Sandmaier BM, Maloney DG, Deeg HJ . Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy. Bone Marrow Transplant 2012; 47: 804–809.

    Article  CAS  Google Scholar 

  5. Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia 2013; 27: 1229–1235.

    Article  CAS  Google Scholar 

  6. Schroeder T, Rachlis E, Bug G, Stelljes M, Klein S, Steckel NK et al. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions-a retrospective multicenter analysis from the German cooperative transplant study group. Biol Blood Marrow Transplant 2015; 21: 653–660.

    Article  CAS  Google Scholar 

  7. Zeiser R, Bertz H, Spyridonidis A, Houet L, Finke J . Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives. Bone Marrow Transplant 2004; 34: 923–928.

    Article  CAS  Google Scholar 

  8. Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010; 116: 1908–1918.

    Article  CAS  Google Scholar 

  9. Weiss L, Melchardt T, Neureiter D, Kemmerling R, Moshir S, Pleyer L et al. Complete remission of Waldenstrom macroglobulinemia with azacitidine and rituximab. J Clin Oncol 2011; 29: e696–e698.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, Duesseldorf, Germany

    T Schroeder, R Fenk, R Haas, U Germing & G Kobbe

Authors
  1. T Schroeder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Fenk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. U Germing
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G Kobbe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Schroeder.

Ethics declarations

Competing interests

TS had a consulting role for Celgene Corporation, Germany and received financial travel support and lecture fees from Celgene Corporation, Germany. RF had a consulting role for Celgene Corporation, Germany and received honoraria, research funding and financial travel support from Celgene Corporation, Germany. UG received a speakers honorarium and research support from Celgene, Novartis and Janssen-Cilag. GK received financial travel support, research funding and lecture fees from Celgene Corporation. The remaining author declares no conflict of interest.

Additional information

Author contributions

TS and GK wrote the manuscript. All the authors gave final approval of the manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schroeder, T., Fenk, R., Haas, R. et al. Reply to ‘Allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome’. Bone Marrow Transplant 50, 1483–1485 (2015). https://doi.org/10.1038/bmt.2015.176

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.176

Search

Advanced search

Quick links